ES2150378B1 - Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. - Google Patents

Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.

Info

Publication number
ES2150378B1
ES2150378B1 ES009801708A ES9801708A ES2150378B1 ES 2150378 B1 ES2150378 B1 ES 2150378B1 ES 009801708 A ES009801708 A ES 009801708A ES 9801708 A ES9801708 A ES 9801708A ES 2150378 B1 ES2150378 B1 ES 2150378B1
Authority
ES
Spain
Prior art keywords
disorders
excess
derivatives
substance
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009801708A
Other languages
English (en)
Spanish (es)
Other versions
ES2150378A1 (es
Inventor
Ramon Merce-Vidal
Jordi Frigola-Constansa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Priority to ES009801708A priority Critical patent/ES2150378B1/es
Priority to ARP990103870A priority patent/AR019999A1/es
Priority to CO99049291A priority patent/CO5080747A1/es
Priority to JP2000563228A priority patent/JP2002522359A/ja
Priority to CA002339661A priority patent/CA2339661C/en
Priority to NZ509645A priority patent/NZ509645A/xx
Priority to TR2001/00378T priority patent/TR200100378T2/xx
Priority to AT99940199T priority patent/ATE257379T1/de
Priority to US09/762,079 priority patent/US6518295B1/en
Priority to PT99940199T priority patent/PT1103243E/pt
Priority to PCT/ES1999/000255 priority patent/WO2000007542A2/es
Priority to DE69914085T priority patent/DE69914085T8/de
Priority to RU2001106644/15A priority patent/RU2223116C2/ru
Priority to HU0105428A priority patent/HUP0105428A3/hu
Priority to EP99940199A priority patent/EP1103243B1/en
Priority to AU54229/99A priority patent/AU754124B2/en
Priority to KR1020017001560A priority patent/KR100558506B1/ko
Priority to ES99940199T priority patent/ES2213380T3/es
Priority to DK99940199T priority patent/DK1103243T3/da
Priority to CZ2001412A priority patent/CZ292065B6/cs
Priority to PL99346221A priority patent/PL193802B1/pl
Priority to TW088113353A priority patent/TW445259B/zh
Priority to CNB998109150A priority patent/CN1151789C/zh
Priority to BR9912807-1A priority patent/BR9912807A/pt
Publication of ES2150378A1 publication Critical patent/ES2150378A1/es
Priority to ZA200100867A priority patent/ZA200100867B/en
Priority to NO20010634A priority patent/NO20010634L/no
Priority to IL14129501A priority patent/IL141295A0/xx
Application granted granted Critical
Publication of ES2150378B1 publication Critical patent/ES2150378B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES009801708A 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. Expired - Fee Related ES2150378B1 (es)

Priority Applications (27)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
CO99049291A CO5080747A1 (es) 1998-08-07 1999-08-04 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p
ARP990103870A AR019999A1 (es) 1998-08-07 1999-08-04 Empleo de derivados de aril(heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso desustancia p.
DK99940199T DK1103243T3 (da) 1998-08-07 1999-08-05 Anvendelse af aryl(eller heteroaryl)azolylcarbinol-derivater til behandling af lidelser medieret af et overskud af substans P
NZ509645A NZ509645A (en) 1998-08-07 1999-08-05 Utilization of phenyl or thienyl subtituted imidazole or pyrazole carbinol derivatives for treating conditions mediated by an excess of substance P
TR2001/00378T TR200100378T2 (tr) 1998-08-07 1999-08-05 P-maddesi aşırısının aracılık ettiği hastalıkların tedavisindeki ilaç
AT99940199T ATE257379T1 (de) 1998-08-07 1999-08-05 Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden
US09/762,079 US6518295B1 (en) 1998-08-07 1999-08-05 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P
PT99940199T PT1103243E (pt) 1998-08-07 1999-08-05 Utilizacao de derivados aril(ou heteroaril)azolilcarbinol na preparacao de um medicamento para o tratamento de problemas mediados por um excesso de substancia p
PCT/ES1999/000255 WO2000007542A2 (es) 1998-08-07 1999-08-05 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p
DE69914085T DE69914085T8 (de) 1998-08-07 1999-08-05 Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden
RU2001106644/15A RU2223116C2 (ru) 1998-08-07 1999-08-05 Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p
HU0105428A HUP0105428A3 (en) 1998-08-07 1999-08-05 Utilization of aryl or heteroaryl-azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p
EP99940199A EP1103243B1 (en) 1998-08-07 1999-08-05 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives for the treatment of troubles mediated by an excess of substance p
JP2000563228A JP2002522359A (ja) 1998-08-07 1999-08-05 過剰のサブスタンスpによって仲介される障害の処置用医薬の製造におけるアリール(またはヘテロアリール)アゾリルカルビノール誘導体の使用
KR1020017001560A KR100558506B1 (ko) 1998-08-07 1999-08-05 과도한 물질 p에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도
ES99940199T ES2213380T3 (es) 1998-08-07 1999-08-05 Uso de derivados de aril(o heteroaril)azolilcarbinoles para el tratamiento de los trastornos mediados por un exceso de substancia p.
CA002339661A CA2339661C (en) 1998-08-07 1999-08-05 Use of derivatives of aryl(or heteroaryl)azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance p
CZ2001412A CZ292065B6 (cs) 1998-08-07 1999-08-05 Použití derivátů aryl (nebo heteroaryl)azolylkarbinolů pro přípravu léčiv k léčení chorob zprostředkovaných přebytkem substance P
PL99346221A PL193802B1 (pl) 1998-08-07 1999-08-05 Zastosowanie pochodnych arylo (lub heteroarylo) azolilokarbinoli do wytwarzania leku do leczenia zaburzeń wywoływanych nadmiarem substancji P
TW088113353A TW445259B (en) 1998-08-07 1999-08-05 Use of derivatives of aryl (or heteroaryl) azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance P
CNB998109150A CN1151789C (zh) 1998-08-07 1999-08-05 芳基(或杂芳基)吡咯基甲醇的衍生物的应用
BR9912807-1A BR9912807A (pt) 1998-08-07 1999-08-05 Uso de derivados de arila (ou heteroarila) azolilcarbinol na fabricação de medicamento para tratamento de distúrbios mediados por excesso de substância p
AU54229/99A AU754124B2 (en) 1998-08-07 1999-08-05 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P
ZA200100867A ZA200100867B (en) 1998-08-07 2001-01-31 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P.
NO20010634A NO20010634L (no) 1998-08-07 2001-02-06 Anvendelse av derivater av aryl (eller heteroaryl)azolylkarbinol ved fremstilling av et medikament for behandling av forstyrrelser formidlet av et overskudd av substans P
IL14129501A IL141295A0 (en) 1998-08-07 2001-02-07 Use of derivatives of aryl (or heteroaryl) azolycarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance p

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.

Publications (2)

Publication Number Publication Date
ES2150378A1 ES2150378A1 (es) 2000-11-16
ES2150378B1 true ES2150378B1 (es) 2001-07-01

Family

ID=8304839

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009801708A Expired - Fee Related ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
ES99940199T Expired - Lifetime ES2213380T3 (es) 1998-08-07 1999-08-05 Uso de derivados de aril(o heteroaril)azolilcarbinoles para el tratamiento de los trastornos mediados por un exceso de substancia p.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99940199T Expired - Lifetime ES2213380T3 (es) 1998-08-07 1999-08-05 Uso de derivados de aril(o heteroaril)azolilcarbinoles para el tratamiento de los trastornos mediados por un exceso de substancia p.

Country Status (26)

Country Link
US (1) US6518295B1 (https=)
EP (1) EP1103243B1 (https=)
JP (1) JP2002522359A (https=)
KR (1) KR100558506B1 (https=)
CN (1) CN1151789C (https=)
AR (1) AR019999A1 (https=)
AT (1) ATE257379T1 (https=)
AU (1) AU754124B2 (https=)
BR (1) BR9912807A (https=)
CA (1) CA2339661C (https=)
CO (1) CO5080747A1 (https=)
CZ (1) CZ292065B6 (https=)
DE (1) DE69914085T8 (https=)
DK (1) DK1103243T3 (https=)
ES (2) ES2150378B1 (https=)
HU (1) HUP0105428A3 (https=)
IL (1) IL141295A0 (https=)
NO (1) NO20010634L (https=)
NZ (1) NZ509645A (https=)
PL (1) PL193802B1 (https=)
PT (1) PT1103243E (https=)
RU (1) RU2223116C2 (https=)
TR (1) TR200100378T2 (https=)
TW (1) TW445259B (https=)
WO (1) WO2000007542A2 (https=)
ZA (1) ZA200100867B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174756B2 (es) * 2001-04-06 2003-11-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias.
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
ES2180449B1 (es) * 2001-07-06 2004-01-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
DE10335566A1 (de) * 2003-07-31 2005-02-24 Grünenthal GmbH Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
EP1784178A1 (en) * 2004-07-30 2007-05-16 Laboratorios Del Dr. Esteve, S.A. Aryl (or heteroaryl) azolylcarbinols
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1690537A1 (en) * 2005-02-15 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia
ES2286920B1 (es) * 2005-02-15 2008-08-16 Laboratorios Del Dr. Esteve, S.A. Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia.
EP1695704A1 (en) * 2005-02-28 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
WO2006087147A2 (en) * 2005-02-15 2006-08-24 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
AU2007209381A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
AU2007312390B2 (en) 2006-10-19 2013-03-28 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
CA2668454A1 (en) 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles
WO2008058867A2 (en) 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
ES2364701T3 (es) 2006-12-13 2011-09-12 F. Hoffmann-La Roche Ag Nuevos 2-imidazoles como ligandos para receptores asociados a aminas trazas.
EP2114906B1 (en) 2007-02-02 2014-08-06 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands for cns disorders
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
WO2009003868A2 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
AU2008270444A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
AU2008285795A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as TAAR1 ligands
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
WO2010123999A2 (en) * 2009-04-21 2010-10-28 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2017157873A1 (en) 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613720B1 (fr) * 1987-04-10 1990-01-19 Esteve Labor Dr Derives d'aryl-heteroaryl carbinols avec activite analgesique
FR2681322B1 (fr) * 1991-09-12 1993-12-17 Laboratorios Dr Esteve Sa Derives d'aryl-heteroaryl-{n-[2-(3,4-dimethoxyphenyl)-ethyl]-n-methyl-3-aminopropoxy}-methane leur preparation et leur application en tant que medicaments .
CA2154116A1 (en) * 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists
FR2742147B1 (fr) * 1995-12-06 1998-02-27 Esteve Labor Dr Procede de separation de carbinols
CA2273807A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders
CA2273853A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
EP0942734A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating severe anxiety disorders
DE69732133T2 (de) * 1996-12-02 2005-12-22 Merck Sharp & Dohme Ltd., Hoddesdon Verwendung von NK-1 Rezeptorantagonisten zur Behandlung von schweren Depressionen
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
CO5080747A1 (es) 2001-09-25
EP1103243B1 (en) 2004-01-07
CZ2001412A3 (cs) 2001-08-15
KR100558506B1 (ko) 2006-03-07
KR20010079616A (ko) 2001-08-22
CA2339661A1 (en) 2000-02-17
ATE257379T1 (de) 2004-01-15
CN1151789C (zh) 2004-06-02
JP2002522359A (ja) 2002-07-23
ES2150378A1 (es) 2000-11-16
HUP0105428A3 (en) 2003-01-28
DK1103243T3 (da) 2004-05-03
BR9912807A (pt) 2001-10-16
AU5422999A (en) 2000-02-28
WO2000007542A2 (es) 2000-02-17
NO20010634L (no) 2001-04-06
AU754124B2 (en) 2002-11-07
PL346221A1 (en) 2002-01-28
US6518295B1 (en) 2003-02-11
WO2000007542A3 (es) 2000-05-11
TW445259B (en) 2001-07-11
NO20010634D0 (no) 2001-02-06
ZA200100867B (en) 2001-08-16
PL193802B1 (pl) 2007-03-30
CN1317966A (zh) 2001-10-17
DE69914085T8 (de) 2005-04-21
AR019999A1 (es) 2002-03-27
CA2339661C (en) 2006-10-17
IL141295A0 (en) 2002-12-01
RU2223116C2 (ru) 2004-02-10
CZ292065B6 (cs) 2003-07-16
EP1103243A2 (en) 2001-05-30
DE69914085D1 (de) 2004-02-12
NZ509645A (en) 2003-01-31
ES2213380T3 (es) 2004-08-16
TR200100378T2 (tr) 2001-06-21
DE69914085T2 (de) 2004-11-25
HUP0105428A2 (hu) 2002-05-29
PT1103243E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
ES2150378B1 (es) Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
PA8487601A1 (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer
ES2099282T3 (es) Derivados de beta-aminoacidos substituidos utiles como inhibidores de la agregacion de plaquetas.
AR002289A1 (es) Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias.
WO2004056324A3 (en) Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
CL2003002050A1 (es) Compuestos derivados de 1-piperazin-1,2-dihidroindeno, su composicion farmaceutica y el uso de esta para tratar enfermedades del sistema nervioso central.
UY26130A1 (es) Compuestos para tratar la obesidad
PE20010130A1 (es) Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion
PT1586319E (pt) Inibidores de gsk-3
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
DK1104758T3 (da) Acetylenderivativer som anti-inflammatoriske/analgesiske lægemidler
YU84791A (sh) Biciklicni 1-aza-cikloalkalni
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
AR029025A1 (es) Derivados de adenosina n6 heterociclicos 5' modificados, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento
BR9802005A (pt) Derivado de pirazola tricìclico
AR026711A1 (es) Derivados de heterociclo-alquilsulfonil-pirazol como agentes anti-inflamatorios /analgesicos
AR035685A1 (es) Derivados de isoxazolina, sus prodrogas, composiciones farmaceuticas que comprenden dichos compuestos, procesos para preparar dichas composiciones, uso de dichos compuestos para la fabricacion de medicamentos, uso de dichas composiciones para la fabricacion de medicamentos, procesos para la preparac
AR013844A1 (es) Compuestos derivados de 3-oxo-pirido[1,2-a] bencimidazol-4-carboxamida sustituidos en posicion 5 con alquilo que contiene heteroatomo,- y composiciones farmaceuticas que los comprenden.
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
ES2137136A1 (es) Empleo de derivados de aril (o heteroaril) azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica.
CY1107145T1 (el) Παραγωγα εστριενο[3,2-b]/[3,4-c]πυρρολης χρησιμα ως ρυθμιστες των υποδοχεων οιστρογονων
PA8471901A1 (es) Derivados de 2"-desoxi higromicina
UY26485A1 (es) "pirroles sustituidos"

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20001116

Kind code of ref document: A1

Effective date: 20001116

FD2A Announcement of lapse in spain

Effective date: 20180807